| CTRI Number |
CTRI/2024/04/066390 [Registered on: 26/04/2024] Trial Registered Prospectively |
| Last Modified On: |
26/04/2024 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
A study to compare injectable iron with oral iron tablets for correction of anemia among patients planned for gynecological surgeries |
|
Scientific Title of Study
|
Preoperative intravenous ferric carboxymaltose versus oral ferrous ascorbate for anaemic patients undergoing elective gynecological surgery – A Randomised controlled trial Pilot Study |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Sayanti Paul |
| Designation |
Assistant Professor |
| Affiliation |
AIIMS, Kalyani |
| Address |
Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital
Nadia WEST BENGAL 741245 India |
| Phone |
09836799167 |
| Fax |
|
| Email |
ichchedana.sayanti@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Sayanti Paul |
| Designation |
Assistant Professor |
| Affiliation |
AIIMS, Kalyani |
| Address |
Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital campus
WEST BENGAL 741245 India |
| Phone |
09836799167 |
| Fax |
|
| Email |
ichchedana.sayanti@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Sayanti Paul |
| Designation |
Assistant Professor |
| Affiliation |
AIIMS, Kalyani |
| Address |
Department of Obstetrics and Gynecology (2nd floor OPD), AIIMS Hospital campus
WEST BENGAL 741245 India |
| Phone |
09836799167 |
| Fax |
|
| Email |
ichchedana.sayanti@gmail.com |
|
|
Source of Monetary or Material Support
|
| Intramural funding,
All India Institute of Medical Sciences
NH34 connector, Saguna, Basantapur
Dist - Nadia, PIN 741245, State - West Bengal |
|
|
Primary Sponsor
|
| Name |
AIIMS, Kalyani |
| Address |
NH34 connector, Basantapur, Kalyani 741245 |
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Sayanti Paul |
All India Institute of Medical Sciences |
2nd Floor OPD, Department of Obstetrics and Gynecology, NH34 connector, Saguna, Basantapur Nadia WEST BENGAL |
9836799167
ichchedana.sayanti@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee AIIMS Kalyani |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: D509||Iron deficiency anemia, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Injection ferric carboxymaltose |
Dosing - First group will receive preoperative injection FCM 15mg/kg maximum 1000 mg 4 weeks prior to surgery.
FCM will be diluted in 100-200 ml saline and infused over 20-30 mins. Patients will be kept under observation for 1 hour post infusion in gynecology day care.
There is provision of second dose of 500 mg FCM injection if preoperative hemoglobin level fails to rise above 10gm/dl 4 weeks after first dose. Cumulative dose of FCM should not be more than 1500 mg/dl for a single patient.
Surgery will be done at least 2 weeks after the second dose of injection FCM if received.
|
| Comparator Agent |
Oral Ferrous Ascorbate tablet |
Dosing - Oral tablet Ferrous Ascorbate 100 mg twice daily 1 hour after food for 4 weeks.
There is provision of giving another 4 weeks of ferrous ascorbate if preoperative hemoglobin fails to rise upto 10 gm/dl 4 weeks after starting oral treatment. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
70.00 Year(s) |
| Gender |
Female |
| Details |
1.Patients with Hemoglobin concentration between 8-12gm/dl and low serum ferritin transferrin saturation or raised TIBC who have been scheduled for elective major gynecological surgeries
2.Patients who are willing to participate and give consent
|
|
| ExclusionCriteria |
| Details |
1.Patients who are pregnant
2.Patients suffering from other forms of anemia except iron deficiency
3.Patients having known hypersensitivity to FCM
4.Patients suffering from Iron storage disorders
5.Patient having serious medical condition or uncontrolled systemic disorders that would prohibit her from participating in the investigation
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
1.Change in hemoglobin (gm/dl) from baseline to day of surgery
2.Change in serum ferritin (ng/ml) from baseline to 1 month after surgery
|
4 weeks before operation
Day of surgery
1 month after surgery
|
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1.Proportion of patients requiring perioperative red blood cell transfusion
2.Postoperative complications within 30 days of surgery (e.g. surgical site infections, venous thromboembolism, cardiovascular events, respiratory failure, acute kidney injury, sepsis, death)
3.Length of postoperative hospital stay (days)
4.Changes in the Quality-of-life score on WHOQOL-BREF questionnaire at recruitment and 1 month after surgery
5.Number and severity of adverse reactions related to study medications during treatment period.
6.Measurement: Incidence and severity of side effects related to oral iron or FCM, such as gastrointestinal disturbances, allergic reactions and changes in serum vitamin D and phosphorus level.
7.Change in hemoglobin from baseline to day 2 post-op
8.Number of patients screened, eligible, enrolled, completed - to assess recruitment and retention rates
|
4 weeks before operation
Day of surgery
Post operative day 2
1 month after surgery
|
|
|
Target Sample Size
|
Total Sample Size="100" Sample Size from India="100"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
01/06/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Background and
Rationale- Preoperative anemia is an independent risk factor for postoperative
morbidity, mortality, and blood transfusions. There is very high prevalence of
iron deficiency anemia in India and women of reproductive age group suffering
from gynecological diseases are more prone to develop the same. Rapid and
timely correction of iron deficiency anemia before elective gynecological
surgery may improve postoperative recovery and may have long term impact on
quality of life. However previous studies have shown mixed results and well-designed
randomized controlled trials on the same study population from India are
lacking. Hence, we propose to perform a randomized controlled trial pilot study
to compare Ferric carboxymaltose (FCM) versus oral iron for postoperative
recovery among anemic women undergoing elective gynecological surgeries.
Objectives –
a. Primary
Objective
i. To compare
change of pre and postoperative blood parameters (hemoglobin and ferritin) between two groups.
b.
Secondary objectives
i. To compare
postoperative morbidity including blood transfusion requirements between two
groups
ii. Comparison
of treatment related adverse effects between two groups.
iii. Comparison
of changes in the quality of life score (WHOQOL- BREF) between two groups
iv. To assess
feasibility of study design in terms of recruitment rates, implementation
barriers and attrition rate
Study Methods-
It will be an open level parallel group randomized controlled trial including
50 patients in each group and study will be conducted over 1 year in the
department of Obstetrics and Gynecology, AIIMS Kalyani. Willing patients with
hemoglobin 8-12gm/dl planned for elective gynecological surgeries will be
included in this study after confirming iron deficiency anemia and ruling out
the exclusion criteria. All recruited patients will be randomly allocated to
ferric carboxymaltose or oral iron group. Patients in FCM group will receive
injection FCM 15mg/kg in gynecology day care 4 weeks prior to elective surgery and
patients in oral iron group will receive oral ferrous ascorbate 100 mg twice
daily till surgery for 4 weeks. Follow-up will be done till 1 month after
surgery.
Study will be
registered under CTRI and any serious drug related serious adverse events will
be notified to the appropriate authority as per Institute protocol.
Study outcomes
–
a. Primary Outcomes:
i. Change in hemoglobin
(gm/dl) from baseline to day of surgery and 1 month after surgery
ii. Change in serum ferritin
(ng/ml) from baseline to 1 month after surgery
b. Secondary Outcomes:
i. Proportion of patients
requiring perioperative red blood cell transfusion
ii. Postoperative
complications within 30 days of surgery (e.g. surgical site infections, venous
thromboembolism, cardiovascular events, respiratory failure, acute kidney
injury, sepsis, death)
iii. Length of postoperative
hospital stay (days)
iv. Changes in the Quality-of-life
score on WHOQOL-BREF questionnaire at recruitment and 1 month after surgery
v. Number and severity of
adverse reactions related to study medications during treatment period.
vi. Measurement: Incidence and
severity of side effects related to oral iron or FCM, such as gastrointestinal
disturbances, allergic reactions and changes in serum vitamin D and phosphorus
level.
vii. Number of patients
screened, eligible, enrolled, completed - to assess recruitment and retention
rates |